Business Description
ArriVent BioPharma is a Pennsylvania-based drug development company focused on creating new treatments for cancer patients who have limited options. Its most advanced drug, firmonertinib, targets specific genetic mutations found in a common form of lung cancer and is currently being tested in several clinical trials. The company is also working on additional therapies aimed at gastrointestinal and other solid tumor cancers. Founded in 2021, ArriVent works alongside several partner organizations to advance its pipeline of experimental treatments.
